GlassScriptPhysician profile
Neil Nepola
NPI 1942261177
$13,680.73
in general payments reported to CMS, 2019-2025
32 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2020: $1,651 · 2021: $2,164 · 2022: $2,485 · 2023: $2,281 · 2024: $1,627 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,361.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,340.78 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $1,687.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,315.42 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $965.10 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $789.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $658.82 | 2019-2025 | Trintellix |
| Abbvie INC. | $647.75 | 2021-2024 | |
| Esperion Therapeutics, INC. | $498.55 | 2020-2024 | Nexletol |
| Amgen INC. | $482.69 | 2019-2023 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $414.41 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $348.59 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $328.43 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $301.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $252.69 | 2019-2020 | |
| Kyowa Kirin, INC. | $197.56 | 2024 | Crysvita |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $196.29 | 2022-2025 | Quviviq, Quviviq |
| Regeneron Healthcare Solutions, INC. | $183.93 | 2021-2022 | |
| Astellas Pharma US INC | $158.43 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.70 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $124.57 | 2022-2025 | Gvoke Hypopen |
| Eisai INC. | $124.23 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $119.69 | 2021 | |
| Intra-Sana Laboratories | $64.81 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Currax Pharmaceuticals LLC | $63.19 | 2023-2025 | Contrave |
| Amarin Pharma, INC. | $54.17 | 2020 | |
| Insmed, INC. | $53.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.78 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $41.03 | 2019-2020 | |
| Philips North America LLC | $19.89 | 2021 | |
| Bausch Health US, LLC | $16.79 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Nepola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.